Aerie Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AERI)

$60.20 1.25 (2.12 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$60.20
Today's Range$58.75 - $60.53
52-Week Range$35.50 - $66.60
Volume190,262 shs
Average Volume505,321 shs
Market Capitalization$2.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AERI
CUSIPN/A
Phone+1-919-3139650

Debt

Debt-to-Equity Ratio0.78%
Current Ratio15.24%
Quick Ratio15.24%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book19.05

Profitability

Trailing EPS($3.35)
Net Income$-99,050,000.00
Net MarginsN/A
Return on Equity-86.87%
Return on Assets-41.89%

Miscellaneous

Employees95
Outstanding Shares36,710,000

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its earnings results on Wednesday, August, 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.02. View Aerie Pharmaceuticals' Earnings History.

Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2017?

13 analysts have issued twelve-month target prices for Aerie Pharmaceuticals' stock. Their predictions range from $48.00 to $100.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $71.85 in the next twelve months. View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "With no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. Aerie had to withdraw its NDA in the United States submitted in 2016 as a third-party manufacturing facility in Tampa, FL, not being ready for pre-approval inspection. The delay in the NDA filing was quite disappointing as Rhopressa is Aerie’s lead late-stage candidate. Any such delays will adversely impact prospects. Aerie resubmitted its NDA for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa’s approval. A potential approval of Rhopressa will boost the company’s growth prospects. Aerie’s shares have outperformed the industry in the last six months." (11/22/2017)
  • 2. Mizuho analysts commented, "We do not view quarterly earnings as an important performance measure of companies like Aerie as valuation is primarily driven by progress of the R&D pipeline." (11/9/2017)
  • 3. HC Wainwright analysts commented, "Blueprint reported a Q1 net loss of $28MM and ended the quarter with $452MM." (5/3/2017)
  • 4. Aegis analysts commented, "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us. 30% of the patients in the Rhopressa arm of the trial discontinued treatment by month 6 compared to 12% of the patient population in the Timolol arm. The most common reason for discontinuation seen in the Rhopressa arm was related to adverse events, at about 19.4%. 2.2% (8) of the subjects in the Timolol arm dropped out due to adverse events. As a point of reference, given that 47% of patients (118 out of 251 patients) on Rhopressa QD completed the treatment by month 12 in Rocket 2, we estimate a maximum drop-off rate of Rhopressa at 53%. Further, according to results published in Persistency: A New Take on Patient Care" by Schwartz in Review of Ophthalmology 11.4 (2004): 108, the discontinuation rates of 66%/50%/46% for Latanoprost/Travoprost/Bimatoprost were seen at month 3 and 6, with rates increasing to 67%/81%/81%, respectively, at month 12." (4/13/2017)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:

  • Vicente Anido Jr., Ph.D., Chairman of the Board, Chief Executive Officer (Age 64)
  • Thomas A. Mitro, President, Chief Operating Officer (Age 59)
  • Casey C. Kopczynski Ph.D., Co-Founder, Chief Scientific Officer (Age 55)
  • Richard J. Rubino CPA, Chief Financial Officer, Secretary (Age 59)
  • Deanne F. Melloy, Vice President - Marketing
  • Tori Arens, Vice President - Drug Product Manufacturing
  • Eric Carlson, Vice President - Research & Development
  • Gerald D. Cagle Ph.D., Independent Director (Age 72)
  • Richard J. Croarkin, Independent Director (Age 62)
  • Michael M. Du Toit, Independent Director (Age 64)

Who owns Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Jennison Associates LLC (5.17%), Orbimed Advisors LLC (3.92%), Bank of New York Mellon Corp (1.51%), Columbus Circle Investors (1.43%), Russell Investments Group Ltd. (1.07%) and Sectoral Asset Management Inc (1.02%). Company insiders that own Aerie Pharmaceuticals stock include Foresite Capital Fund Ii, LP, Geoffrey M Duyk and Gerald D Cagle. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Who sold Aerie Pharmaceuticals stock? Who is selling Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sectoral Asset Management Inc, Prudential Financial Inc., Tocqueville Asset Management L.P., New York State Common Retirement Fund, Granite Point Capital Management L.P., Sei Investments Co. and Rice Hall James & Associates LLC. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Foresite Capital Fund Ii, LP and Geoffrey M Duyk. View Insider Buying and Selling for Aerie Pharmaceuticals.

Who bought Aerie Pharmaceuticals stock? Who is buying Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Columbus Circle Investors, Suffolk Capital Management LLC, Alyeska Investment Group L.P., Bank of New York Mellon Corp, Point72 Asset Management L.P., Axiom International Investors LLC DE and Teachers Retirement System of The State of Kentucky. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy Aerie Pharmaceuticals stock?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $60.20.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $2.21 billion. The company earns $-99,050,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Aerie Pharmaceuticals employs 95 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 7020 Kit Creek Rd Ste 270, RESEARCH TRIANGLE PARK, NC 27709-0014, United States. The company can be reached via phone at +1-919-3139650 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  429 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aerie Pharmaceuticals (NASDAQ:AERI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.932.932.922.92
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $71.21$70.71$66.38$64.42
Price Target Upside: 19.29% upside10.79% upside15.55% upside15.24% upside

Aerie Pharmaceuticals (NASDAQ:AERI) Consensus Price Target History

Price Target History for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Canaccord GenuitySet Price TargetBuy$73.00N/AView Rating Details
11/16/2017Cantor FitzgeraldSet Price TargetBuy$69.00N/AView Rating Details
11/9/2017MizuhoReiterated RatingBuy$87.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$80.00N/AView Rating Details
10/16/2017Needham & Company LLCReiterated RatingBuy -> Buy$65.00 -> $76.00N/AView Rating Details
10/11/2017JMP SecuritiesSet Price TargetBuy$68.00N/AView Rating Details
10/5/2017CowenReiterated RatingBuyN/AView Rating Details
8/2/2017HC WainwrightSet Price TargetBuy$69.00HighView Rating Details
7/28/2017Stifel NicolausReiterated RatingBuy$70.00MediumView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 -> $70.00HighView Rating Details
3/9/2017Raymond James FinancialDowngradeStrong-Buy -> Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank of CanadaBoost Price TargetOutperform$54.00 -> $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings History and Estimates Chart

Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ AERI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017($0.84)($0.82)ViewListenView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.94 EPS
Next Year EPS Consensus Estimate: $-2.51 EPS

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.36%
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.00View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.33View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aerie Pharmaceuticals (NASDAQ AERI) News Headlines

Source:
DateHeadline
Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report?Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report?
finance.yahoo.com - December 11 at 9:43 AM
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
finance.yahoo.com - December 7 at 9:53 AM
Biotech drug pricing should not get substantially worse next year - Mizuho - Seeking AlphaBiotech drug pricing should not get substantially worse next year - Mizuho - Seeking Alpha
seekingalpha.com - December 6 at 3:28 PM
Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region - Business Wire (press release)
www.businesswire.com - December 6 at 9:46 AM
Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast RegionAerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
finance.yahoo.com - December 4 at 9:28 AM
Zacks: Brokerages Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Post -$1.44 Earnings Per ShareZacks: Brokerages Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Post -$1.44 Earnings Per Share
www.americanbankingnews.com - December 3 at 3:26 PM
Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer - PR Newswire (press release)Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer - PR Newswire (press release)
www.prnewswire.com - December 1 at 12:26 PM
Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources - Business Wire (press release)
www.businesswire.com - December 1 at 12:26 PM
Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human ResourcesAerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
finance.yahoo.com - December 1 at 12:26 PM
Aerie Pharmaceuticals, Inc. (AERI) Given Consensus Rating of "Buy" by BrokeragesAerie Pharmaceuticals, Inc. (AERI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 27 at 4:26 PM
Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics - Business Wire (press release)
www.businesswire.com - November 27 at 8:17 AM
Global Ophthalmic Therapeutics/Drug Market 2014-2017 & Forecasts to 2025 - Market is Expected to Reach USD 35.7 BillionGlobal Ophthalmic Therapeutics/Drug Market 2014-2017 & Forecasts to 2025 - Market is Expected to Reach USD 35.7 Billion
www.bizjournals.com - November 24 at 3:21 PM
FY2018 Earnings Estimate for Aerie Pharmaceuticals, Inc. (AERI) Issued By Cantor FitzgeraldFY2018 Earnings Estimate for Aerie Pharmaceuticals, Inc. (AERI) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 22 at 2:48 PM
Aerie Pharmaceuticals, Inc. (AERI) Stock Rating Lowered by Zacks Investment ResearchAerie Pharmaceuticals, Inc. (AERI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 22 at 9:36 AM
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements ... - Business Wire (press release)Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements ... - Business Wire (press release)
www.businesswire.com - November 18 at 3:34 PM
Critical Analysis: Aerie Pharmaceuticals (AERI) versus The CompetitionCritical Analysis: Aerie Pharmaceuticals (AERI) versus The Competition
www.americanbankingnews.com - November 18 at 1:30 PM
Aerie Pharmaceuticals, Inc. (AERI) Given a $73.00 Price Target by Canaccord Genuity AnalystsAerie Pharmaceuticals, Inc. (AERI) Given a $73.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - November 18 at 12:52 PM
BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trialBRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
www.reuters.com - November 18 at 5:47 AM
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in JapanAerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
finance.yahoo.com - November 18 at 5:47 AM
Aerie Pharmaceuticals Target of Unusually Large Options Trading (AERI)Aerie Pharmaceuticals Target of Unusually Large Options Trading (AERI)
www.americanbankingnews.com - November 17 at 1:26 AM
Aerie Pharmaceuticals, Inc. (AERI) Given a $69.00 Price Target at Cantor FitzgeraldAerie Pharmaceuticals, Inc. (AERI) Given a $69.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - November 16 at 6:50 PM
 Analysts Expect Aerie Pharmaceuticals, Inc. (AERI) Will Post Earnings of -$0.67 Per Share Analysts Expect Aerie Pharmaceuticals, Inc. (AERI) Will Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - November 15 at 7:14 AM
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus - NasdaqAerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus - Nasdaq
www.nasdaq.com - November 9 at 4:33 PM
Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update - Business Wire (press release)Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update - Business Wire (press release)
www.businesswire.com - November 9 at 4:33 PM
Is a Surprise Coming for Aerie (AERI) This Earnings Season? - NasdaqIs a Surprise Coming for Aerie (AERI) This Earnings Season? - Nasdaq
www.nasdaq.com - November 7 at 10:12 PM
Aerie Pharmaceuticals (AERI) Buy Rating Reaffirmed at MizuhoAerie Pharmaceuticals' (AERI) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - November 4 at 10:52 PM
Aerie Pharmaceuticals, Inc. (AERI) Receives Consensus Recommendation of "Buy" from AnalystsAerie Pharmaceuticals, Inc. (AERI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 5:48 PM
Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday ... - Business Wire (press release)Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday ... - Business Wire (press release)
www.businesswire.com - November 1 at 3:54 PM
Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs - Business Wire (press release)
www.businesswire.com - October 30 at 3:58 PM
Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical AffairsAerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs
finance.yahoo.com - October 30 at 3:58 PM
-$0.62 EPS Expected for Aerie Pharmaceuticals, Inc. (AERI) This Quarter-$0.62 EPS Expected for Aerie Pharmaceuticals, Inc. (AERI) This Quarter
www.americanbankingnews.com - October 25 at 7:10 PM
Aerie Pharmaceuticals, Inc. (AERI) Research Coverage Started at GuggenheimAerie Pharmaceuticals, Inc. (AERI) Research Coverage Started at Guggenheim
www.americanbankingnews.com - October 23 at 6:50 PM
Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie PharmaStock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie Pharma
www.bizjournals.com - October 20 at 3:45 PM
Aerie Pharmaceuticals (AERI) "Positive" Rating Reiterated at Canaccord GenuityAerie Pharmaceuticals' (AERI) "Positive" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - October 16 at 9:54 AM
Aerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from MizuhoAerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Mizuho
www.americanbankingnews.com - October 16 at 6:30 AM
Aerie Pharma (AERI) Reports Trading Halt Ahead of Advisory Committee for RhopressaAerie Pharma (AERI) Reports Trading Halt Ahead of Advisory Committee for Rhopressa
www.streetinsider.com - October 14 at 8:29 PM
Aerie Pharmaceuticals Announces FDA Advisory Committee Vote In Favor Of Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%Aerie Pharmaceuticals Announces FDA Advisory Committee Vote In Favor Of Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%
www.thestreet.com - October 14 at 8:29 PM
BRIEF-Aerie Pharmaceuticals says ‍FDA committee to review NDA for RhopressaBRIEF-Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
www.reuters.com - October 13 at 8:31 PM
Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment - MarketWatchAerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment - MarketWatch
www.marketwatch.com - October 13 at 3:29 PM
Aerie Pharmaceuticals Stock Trading Halted TodayAerie Pharmaceuticals Stock Trading Halted Today
finance.yahoo.com - October 13 at 3:29 PM
Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatmentAerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment
finance.yahoo.com - October 13 at 3:29 PM
U.S. FDA panel backs Aeries glaucoma drug RhopressaU.S. FDA panel backs Aerie's glaucoma drug Rhopressa
finance.yahoo.com - October 13 at 3:29 PM
Aerie Pharmaceuticals Inc. (AERI) Leaped To A New High After FDA ReviewAerie Pharmaceuticals Inc. (AERI) Leaped To A New High After FDA Review
www.rttnews.com - October 13 at 2:20 AM
Aerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher - NasdaqAerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher - Nasdaq
www.nasdaq.com - October 12 at 4:18 PM
Biotech Analysis Central: Daily Pharma News - Oct. 12, 2017 - Seeking AlphaBiotech Analysis Central: Daily Pharma News - Oct. 12, 2017 - Seeking Alpha
seekingalpha.com - October 12 at 4:18 PM
Mid-Afternoon Market Update: Hudson Technologies Drops Amid Concerning Guidance; Aerie Pharmaceutical Shares ... - BenzingaMid-Afternoon Market Update: Hudson Technologies Drops Amid Concerning Guidance; Aerie Pharmaceutical Shares ... - Benzinga
www.benzinga.com - October 12 at 2:41 AM
Aerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord GenuityAerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord Genuity
www.americanbankingnews.com - October 11 at 7:44 PM
Aerie Pharmas FDA Briefing Docs: Good News With No Surprises; Shares Scale A RecordAerie Pharma's FDA Briefing Docs: Good News With No Surprises; Shares Scale A Record
www.msn.com - October 11 at 4:38 PM
Aeries glaucoma drug effectively lowers eye pressure: FDA reviewAerie's glaucoma drug effectively lowers eye pressure: FDA review
www.reuters.com - October 11 at 4:38 PM
Aerie Pharmaceuticals Inc. (AERI) Has Jumped To A New High On FDA NewsAerie Pharmaceuticals Inc. (AERI) Has Jumped To A New High On FDA News
www.nasdaq.com - October 11 at 4:38 PM

SEC Filings

Aerie Pharmaceuticals (NASDAQ:AERI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aerie Pharmaceuticals (NASDAQ:AERI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aerie Pharmaceuticals (NASDAQ AERI) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.